In this case, nicknamed the Doryx case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of Warner-Chilcott’s branded drug, Doryx (delayed-release doxycycline hyclate). The case alleges that Warner-Chilcott and its licensor, Mayne Pharmaceuticals, to forestall competition from less-expensive generic versions of Doryx, hatched an anticompetitive scheme that included last-minute changes to their product whose only real value was to delay generic competition, thereby violating § 2 of the Sherman Act. The case alleges that Warner-Chilcott and Mayne’s scheme permitted them to charge Plaintiffs and members of the class artificially inflated prices for their purchases of delayed- release doxycycline hyclate. Faruqi & Faruqi LLP was appointed co-lead counsel by the Court. The case ultimately settled for $15 million in late 2013.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 07/18/2012
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Neill W. Clark email@example.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771